Transcode Therapeutics (RNAZ) Interest Expenses (2020 - 2025)
Transcode Therapeutics' (RNAZ) quarterly Interest Expenses came in at $38771.0 in Q4 2025, up 564.21% YoY from $5837.1 in Q4 2024, and down 43.37% on a QoQ basis from $68459.0 in Q3 2025.
Transcode Therapeutics (RNAZ) Interest Expenses (2020 - 2025) Analysis & Trends
Transcode Therapeutics (RNAZ) has 6 years of Interest Expenses data on file, last reported at $38771.0 in Q4 2025.
- Quarterly Interest Expenses rose 564.21% year-over-year to $38771.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $175946.0 (down 29.85% YoY) and the FY2025 annual result came in at $22.8 million, up 41.43% from the prior year.
- Interest Expenses slipped to $38771.0 in Q4 2025, from $68459.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $6.4 million in Q2 2021 to a low of -$77200.0 in Q4 2021.
- A 5-year average of $695789.4 and a median of $62730.0 in 2025 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 17938.94% in 2021, down 243.32% in 2021.
- Tracing RNAZ's Interest Expenses over 5 years: stood at -$77200.0 in 2021, then jumped by 121.36% to $16492.0 in 2022, then slipped by 25.26% to $12326.0 in 2023, then tumbled by 167.76% to -$8352.0 in 2024, then surged by 564.21% to $38771.0 in 2025.
- The last three Interest Expenses figures came in at $38771.0 (Q4 2025), $68459.0 (Q3 2025), and $11715.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 38,771.00 |
| Dec 31, 2025 | 38,771.00 |
| Sep 30, 2025 | 68,459.00 |
| Sep 30, 2025 | 68,459.00 |
| Jun 30, 2025 | 11,715.00 |
| Jun 30, 2025 | 11,715.00 |
| Mar 31, 2025 | 57,001.00 |
| Mar 31, 2025 | 57,001.00 |
| Dec 31, 2024 | -8,352.00 |
| Dec 31, 2024 | -8,352.00 |
| Sep 30, 2024 | 111,190.00 |
| Sep 30, 2024 | 111,190.00 |
| Jun 30, 2024 | 38,480.00 |
| Jun 30, 2024 | 38,480.00 |
| Mar 31, 2024 | 109,483.00 |
| Mar 31, 2024 | 109,483.00 |
| Dec 31, 2023 | 12,326.00 |
| Dec 31, 2023 | 12,326.00 |
| Sep 30, 2023 | 170,582.00 |
| Sep 30, 2023 | 170,582.00 |